PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

DJI 0036
20180131 141122
DJI 0002
IMG-20170807-WA0038
20180815 150808
IMG-20170805-WA0005
  • Human medicines European public assessment report (EPAR): Vildagliptin / Metformin hydrochloride Accord, vildagliptin / metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 24/03/2022, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Don’t Use Products Marketed to Treat Molluscum, a Common Skin Condition
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • Novel Drug Approvals for 2022
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • Drug Trials Snapshot: PYRUKYND
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • Human medicines European public assessment report (EPAR): Empliciti, elotuzumab, Multiple Myeloma, Date of authorisation: 11/05/2016, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Strides Pharma Science Limited - 576722 - 05/23/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • Strides Pharma Science Limited - 576722 - 07/01/2019
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By Center for Drug Evaluation and Research
  • Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Carcinoma, Non-Small-Cell Lung;Mesothelioma, Date of authorisation: 18/01/2016, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Cali Botanicals, LLC - 575320 - 06/11/2019
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By Center for Drug Evaluation and Research
  • IceRx - 1111111 - 10/09/2018
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • FDA and NIH/NCI Center for Cancer Research: Advancing Drug Development in Myelodysplastic Syndromes - 05/16/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
  • Human medicines European public assessment report (EPAR): Rapilysin, reteplase, Myocardial Infarction, Date of authorisation: 29/08/1996, Revision: 27, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Human medicines European public assessment report (EPAR): Sildenafil Actavis, sildenafil, Erectile Dysfunction, Date of authorisation: 10/12/2009, Revision: 16, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Multiple Sclerosis, Date of authorisation: 17/03/2011, Revision: 35, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-06-01
  • Guidance Snapshot Pilot
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-06-01 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.